Deep learning reveals Alzheimer's disease onset in MCI subjects: Results from an international challenge

Journal of Neuroscience Methods
Nicola AmorosoAlzheimer's Disease Neuroimaging Initiative

Abstract

Early diagnosis of Alzheimer's disease (AD) and its onset in subjects affected by mild cognitive impairment (MCI) based on structural MRI features is one of the most important open issues in neuroimaging. Accordingly, a scientific challenge has been promoted, on the international Kaggle platform, to assess the performance of different classification methods for prediction of MCI and its conversion to AD. This work presents a classification strategy based on Random Forest feature selection and Deep Neural Network classification using a mixed cohort including the four classes of classification problem, that is HC, AD, MCI and cMCI, to train the model. Moreover, we compare this approach with a novel classification strategy based on fuzzy logic learned on a mixed cohort including only HC and AD. A training set of 240 subjects and a test set including mixed cohort of 500 real and simulated subjects were used. The data included AD patients, MCI subjects converting to AD (cMCI), MCI subjects and healthy controls (HC). This work ranked third for overall accuracy (38.8%) over 19 participating teams. The "International challenge for automated prediction of MCI from MRI data" hosted by the Kaggle platform has been promoted to validate dif...Continue Reading

Citations

Jun 16, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Hongming LiUNKNOWN Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle Study of Aging
Dec 21, 2018·BMC Medical Informatics and Decision Making·Telma PereiraUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jun 11, 2019·Frontiers in Aging Neuroscience·Nicola AmorosoRoberto Bellotti
Nov 22, 2018·Biomedical Engineering Online·Nicola AmorosoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Nov 6, 2018·Frontiers in Computational Neuroscience·Ahmed A MoustafaHany Alashwal
Nov 28, 2020·The British Journal of Ophthalmology·C Ellis WiselySharon Fekrat
Jan 27, 2021·The British Journal of Ophthalmology·Wei Yan NgDaniel Shu Wei Ting
Dec 15, 2019·Computer Methods and Programs in Biomedicine·Mr Amir EbrahimighahnaviehRaymond Chiong
Oct 27, 2020·Frontiers in Aging Neuroscience·Li KangTijiang Zhang
May 18, 2020·Medical Image Analysis·Junhao WenUNKNOWN Australian Imaging Biomarkers and Lifestyle flagship study of ageing
Dec 16, 2019·Journal of Neuroscience Methods·Parisa ForouzannezhadMalek Adjouadi
May 8, 2020·Neuroscience Letters·Jingwan JiangTijiang Zhang
Jun 15, 2021·Frontiers in Neuroscience·Angela LombardiSabina Tangaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.